Dermatology

This segment of the latest episode of the Skin of Color Savvy podcast highlights key challenges faced by Galaria in her dermatology practice.

In the ongoing JADE EXTEND trial, long-term treatment with abrocitinib led to sustained skin clearance and other improvements through 112 weeks.

In this new Skin of Color Savvy podcast, Noreen Galeria, MD, discusses topics such as patient, misinformation, her career, and research on natural remedies.

In this segment from the April episode of The Medical Sisterhood podcast, the speakers discussed simple ways for physicians to get involved in community service without feeling overwhelmed.

This iteration of the ‘Month in Review’ series highlights top headlines covered in April in dermatology news, including FDA decisions.

Elizabeth Kiracofe, MD, speaks in this segment of her recent The Medical Sisterhood podcast about her career and other community initiatives.

In this Q&A interview, Hordinsky was asked about recent 1-year data on clascoterone solution 5% in androgenetic alopecia (AGA).

Are IL-23 inhibitors, rather than IL-17 inhibitors, the preferred biologic for psoriasis patients at risk of developing psoriatic arthritis?

In this April episode, the discussion highlights how intentional choices and practice ownership can help physicians align professional with personal success.

This Q&A interview with Nambudiri covers the AAD Clinical Image Collection, launched in January 2025 to address diversity in dermatology education.

The International Eczema Council set out to create a set of consensus-based definitions of remission, LDA, and vLDA in atopic dermatitis.

This Q&A interview highlights emerging therapies for atopic dermatitis, featuring Christopher G. Bunick, MD, PhD of Yale Medicine.

54-week STOP-HS safety data for the JAK1-selective inhibitor povorcitinib showed no dose-dependent safety signal and few laboratory abnormalities.

Stay updated with the latest healthcare breakthroughs, including FDA actions and new topline clinical trial data, in this week’s essential news roundup.

In this interview, Nguyen discusses improving patient experiences during surgical procedures in dermatology practices, such as Mohs surgery.

Christopher Bunick, MD, PhD, and colleagues conducted a review bispecific and trispecific antibodies in atopic dermatitis.

In this segment of the interview, questions remaining about AI's effectiveness among patients in dermatology were explored.

Liu and Sayres emphasize that while AI tools improve consumer recognition of skin conditions, gaps remain in prediction accuracy and information.

FDA approved dupilumab for children aged 2 to 11 years with chronic spontaneous urticaria uncontrolled by H1 antihistamines.

This interview highlights new data assessing whether artificial intelligence (AI)–powered tools can help consumers better understand dermatology cases.

At the 2026 AAD Annual Meeting, Nambudiri spoke on various points, including how emerging AI tools may help reduce administrative burden in dermatology.

There is an antifungal-resistant dermatophyte spreading globally, and experts are urging clinicians to become more aware.

54-week STOP-HS data show clinically meaningful improvements in pain, fatigue, and quality of life in one-third to two-thirds of patients.

Phase 2b data from the 16-week extension of REZOLVE-AA suggest rezpegaldesleukin leads to continued hair regrowth through 52 weeks.